Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection

Image credit: American Society of Nephrology


The effects of dapagliflozin on primary and secondary outcomes in hospitalized participants with COVID-19 were consistent in those with eGFR below/above 60 ml/min per 1.73 m2. Dapagliflozin was well tolerated and did not increase the risk of AKI in participants with eGFR below or above 60 ml/min per 1.73 m2.

Samvel B. Gasparyan
Samvel B. Gasparyan

Biostatistician in cardiovascular trials.